Literature DB >> 31630374

Genetic and Clinical Profile of Chinese Patients with Autosomal Dominant Spastic Paraplegia.

Miao Zhao1, Yi-Jun Chen1, Meng-Wen Wang1, Xiao-Hong Lin1, En-Lin Dong1, Wan-Jin Chen1,2, Ning Wang3,4, Xiang Lin5,6.   

Abstract

BACKGROUND: Hereditary spastic paraplegia (HSP) refers to a group of neurodegenerative disorders characterized by bilateral weakness, spasticity, and hyperreflexia in the lower limbs. The autosomal dominant HSP (ADHSP) predominantly presents as the pure form, but the clinical profiles and causal genetic variants underlying ADHSP are complex, and many remain unknown.
METHODS: A cohort of 15 Chinese HSP pedigrees (including 35 patients and their 22 relatives) were screened by multiplex ligation-dependent probe amplification (MLPA) or whole-exome sequencing (WES). Neurological assessments were also conducted.
RESULTS: The main subtypes of HSP above detected in our cohort were SPG4, SPG3A, and SPG6. Fifteen HSP-inducing mutations were identified, among which six were novel mutations: SPAST c.1277T>C, c.1292G>C, c.1562T>C, and c.1693A>T, NIPA1 c.748A>C, and KIDINS220 c.4448C>G. As expected, the most common presentation of the ADHSP cases was the pure form, manifesting spasticity of lower limbs and hyperreflexia, as well as pyramidal signs. Differing substantially from previous reports for KIDINS220 variants, our study family exhibited autosomal dominant inheritance, and only presented with spastic paraplegia, with no signs of intellectual disability, nystagmus, or obesity.
CONCLUSION: Our work reveals a non-classical spastic paraplegia, intellectual disability, nystagmus, and obesity phenotype for a KIDINS220 mutation, which broadens both the clinical and genetic spectrum for ADHSP. Beyond underscoring the utility of using both MLPA and WES in studies of HSP, our work deepens the scientific understanding of phenotypes for ADHSP and defines new genetic variants to facilitate future diagnoses.

Entities:  

Year:  2019        PMID: 31630374     DOI: 10.1007/s40291-019-00426-w

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.074


  6 in total

Review 1.  The 15q11.2 BP1-BP2 Microdeletion (Burnside-Butler) Syndrome: In Silico Analyses of the Four Coding Genes Reveal Functional Associations with Neurodevelopmental Phenotypes.

Authors:  Syed K Rafi; Merlin G Butler
Journal:  Int J Mol Sci       Date:  2020-05-06       Impact factor: 5.923

2.  Chinese patients with hereditary spastic paraplegias (HSPs): a protocol for a hospital-based cohort study.

Authors:  Yu-Sen Qiu; Yi-Heng Zeng; Ru-Ying Yuan; Zhi-Xian Ye; Jin Bi; Xiao-Hong Lin; Yi-Jun Chen; Meng-Wen Wang; Ying Liu; Shao-Bo Yao; Yi-Kun Chen; Jun-Yi Jiang; Yi Lin; Xiang Lin; Ning Wang; Ying Fu; Wan-Jin Chen
Journal:  BMJ Open       Date:  2022-01-11       Impact factor: 2.692

3.  Kidins220/ARMS modulates brain morphology and anxiety-like traits in adult mice.

Authors:  Amanda Almacellas-Barbanoj; Martina Albini; Annyesha Satapathy; Fanny Jaudon; Caterina Michetti; Alicja Krawczun-Rygmaczewska; Huiping Huang; Francesca Manago; Francesco Papaleo; Fabio Benfenati; Fabrizia Cesca
Journal:  Cell Death Discov       Date:  2022-02-09

4.  Clinical and Genetic Features of Chinese Patients With NIPA1-Related Hereditary Spastic Paraplegia Type 6.

Authors:  Jun Fu; Mingming Ma; Gang Li; Jiewen Zhang
Journal:  Front Genet       Date:  2022-04-08       Impact factor: 4.772

5.  Integrating protein networks and machine learning for disease stratification in the Hereditary Spastic Paraplegias.

Authors:  Nikoleta Vavouraki; James E Tomkins; Eleanna Kara; Henry Houlden; John Hardy; Marcus J Tindall; Patrick A Lewis; Claudia Manzoni
Journal:  iScience       Date:  2021-04-28

6.  Novel Compound Missense and Intronic Splicing Mutation in ALDH18A1 Causes Autosomal Recessive Spastic Paraplegia.

Authors:  Yi-Jun Chen; Zai-Qiang Zhang; Meng-Wen Wang; Yu-Sen Qiu; Ru-Ying Yuan; En-Lin Dong; Zhe Zhao; Hai-Tao Zhou; Ning Wang; Wan-Jin Chen; Xiang Lin
Journal:  Front Neurol       Date:  2021-05-19       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.